Suchergebnisse - "Li, Manxiang"

PubPharm (64)

1

Epidemiological features and temporal trends of HIV-negative tuberculosis burden from 1990 to 2019 : a retrospective analysis based on the Global Burden of Disease Study 2019

enthalten in: BMJ open | 2023

von Chen, Y. | Liu, J. | Zhang, Q. | +11

2

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer : a randomized, multicenter, open-label, phase III trial

enthalten in: Signal transduction and targeted therapy | 2023

von Yang, Y. | Min, J. | Yang, N. | +17

3

Antimicrobial resistance and molecular typing of Staphylococcus aureus isolates from raw milk in Hunan Province

enthalten in: PeerJ | 2023

von Ning, K. | Zhou, R. | Li, M.

4

Global burden of asthma associated with high body mass index from 1990 to 2019

enthalten in: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology | 2022

von Liu, J. | Yuan, M. | Chen, Y. | +10

5

CEMIP as a prognostic biomarker for cancers : a meta- and bioinformatic analysis

enthalten in: Expert review of molecular diagnostics | 2022

von Chen, H. | Wang, Q. | Liu, J. | +7

6

Treatable traits in the NOVELTY study

enthalten in: Respirology (Carlton, Vic.) | 2022

von Agustí, A. | Rapsomaniki, E. | Beasley, R. | +107

CommentIn: Respirology. 2022 Nov;27(11):912-913. - PMID 35926852

7

Induction of GLI1 by miR-27b-3p/FBXW7/KLF5 pathway contributes to pulmonary arterial hypertension

enthalten in: Journal of molecular and cellular cardiology | 2022

von Wang, Q. | Chai, L. | Zhang, Q. | +8

8

Frequent productive cough : Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study

enthalten in: Respiratory medicine | 2022

von Hughes, R. | Rapsomaniki, E. | Janson, C. | +107

9

The burden of mild asthma : Clinical burden and healthcare resource utilisation in the NOVELTY study

enthalten in: Respiratory medicine | 2022

von Golam, S. | Janson, C. | Beasley, R. | +110

10

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer : A multicenter, randomized, double-blinded, phase III trial

enthalten in: Cancer communications (London, England) | 2021

von Shi, Y. | Lei, K. | Jia, Y. | +73

1
2
3
4
5
6
7
Nächster »
[7]